Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 78   

Articles published

ARNA 4.33 -0.01 (-0.23%)
price chart
Biotech Equities Technical Updates -- Gilead Sciences, Arena Pharma, ACADIA ...
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), and Juno ...
Stocks Alert: Ambarella Inc (NASDAQ:AMBA), Arena Pharmaceuticals, Inc ...
Arena Pharmaceuticals, Inc., a biopharmaceutical corporation, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
News Review: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ZIOPHARM ...  Market News Call
Biotech Most Active Stocks: ZIOPHARM Oncology (NASDAQ:ZIOP), Gilead ...  Gaining Green
Closing Bell Reports: Horizon Pharma plc (HZNP), Novogen Limited (NVGN ...
Arena Pharmaceuticals, Inc. (ARNA) finished up today at $4.33 with a volume of 2,640,557 shares, changing by -0.23% ( 0.230% change from open).
Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings?
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) is scheduled to report fourth-quarter 2014 results on Mar 2. Last quarter, the company posted a positive earnings surprise of 61.54%.
Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog  Nasdaq
Stocks Ticking Down: Arena Pharmaceuticals, (NASDAQ:ARNA), Rentech ...
Formerly on March 2 2015 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2014.
Weakening Healthcare Stocks for 2015: Arena Pharmaceuticals, Inc. (NASDAQ ...
A better way to describe growth is using percentages, which tells you the amount of growth relative to its initial value. The most recent price of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), is now at a discount to the 12-month high of $7.22 hit on May ...
First Call Rating Update on Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has received a Hold rating from First Call Corporation, a division of Thomson Reuters.
Arena Pharmaceuticals Cut to Underperform at Zacks (ARNA)  WKRB News
Morning Buzz: Kellogg Company (K), Arena Pharmaceuticals, Inc. (ARNA ...
Kellogg Company (K) of the Consumer Goods sector is up 0.02% (change from open -0.91%) this morning trading at a volume of 366,413 shares and price of $62.95.
Arena Pharmaceuticals Inc.: Arena Pharmaceuticals Provides Corporate Update ...
SAN DIEGO, March 2, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2014.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Kept in Lower Notes- Westar ...
Biopharmaceutical company, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) [Trend Analysis] plunged over 2.34% in afterhours trading on Monday after it released that a loss for the Q4 that widened from previous year, despite a revenue increase, reflecting ...